Northwire Canada EditionSaturday, July 18, 2026
Northwire
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Production / Operations

HEALWELL AI and WELL Health Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research

AIDX · Price

Executive Summary

  • HEALWELL AI Inc. and WELL Health Technologies Corp. announced the launch of WELLTRUST™, a consent‑driven patient‑identification platform for clinical research across WELL‑operated clinics in Canada.
  • The platform combines WELL’s extensive outpatient clinic network with HEALWELL’s DARWEN™ AI to securely match high‑fit patients with chronic, rare, and complex conditions to clinical trial opportunities while preserving privacy.
  • WELLTRUST provides a scalable, privacy‑compliant infrastructure that enables pharmaceutical sponsors and research organizations to access consented patient data for trial recruitment, real‑world evidence generation, and future decision‑support tools.

Key Details

  • Platform Name: WELLTRUST™ – “consent‑first” data governance and patient‑identification solution.
  • Collaborators: HEALWELL AI Inc. (TSX: AIDX) and WELL Health Technologies Corp. (TSX: WELL).
  • Geographic Scope: Initial rollout in Canada within WELL‑operated outpatient clinics (Toronto, Ontario; Vancouver, British Columbia, and other locations).
  • Core Functionality:
  • Secure patient consent framework allowing individuals to opt‑in or opt‑out of future outreach for clinical trials and research studies.
  • AI‑enabled identification of “high‑fit” patients using HEALWELL’s DARWEN™ platform, targeting chronic, rare, and complex conditions.
  • Unified privacy, consent, and data‑governance layer meeting Canadian regulatory standards.
  • First Commercial Application: Leveraging the combined clinical footprint and AI to accelerate recruitment for clinical trials, improving enrollment rates and trial success probability.
  • Future Use Cases (planned): Real‑world evidence generation, enhanced clinical decision support tools, and additional research‑related data services.
  • Quotes:
  • Dr. Alexander Dobranowski, President, HEALWELL AI – highlighted the platform’s role in responsible AI and patient autonomy.
  • Dr. Michael Frankel, Chief Medical Officer, WELL Health – emphasized the impact on accelerating therapeutics and diagnostics through a transparent, consent‑driven data infrastructure.
  • Leadership Sign‑off: James Lee (CEO, HEALWELL AI) and Hamed Shahbazi (Chairman & CEO, WELL Health).

Notable Quotes

“WELLTRUST embodies our commitment to responsible and impactful AI in healthcare…accelerating research while respecting high standards of privacy and patient autonomy.” – Dr. Alexander Dobranowski, President, HEALWELL AI

“This launch marks a major step forward in our mission to empower patients and improve healthcare outcomes through the use of technology.” – Dr. Michael Frankel, Chief Medical Officer, WELL Health

Read the original news release →

More from HEALWELL AI INC. J CL A SV